POINT Biopharma to Participate in Upcoming Investor Conferences

3 years ago

INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating…

T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results

3 years ago

Implemented expense reductions including headcount during the second quarterLEXINGTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO),…

Zacks Places Share Value of ABVC BioPharma at $9.50

3 years ago

FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical…

Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study

3 years ago

Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Versus VehicleASHBURN, Va., July 06, 2022 (GLOBE…

Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

3 years ago

SOLANA BEACH, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily…

SciSparc Board of Directors to Promote Buyback Program of up to $1 Million

3 years ago

TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage…

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies

3 years ago

Sarepta and its partner Roche present new results and analyses at the International Congress on Neuromuscular Diseases (ICNMD), which demonstrate…

Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

3 years ago

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to…

Cend Therapeutics Announces Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

3 years ago

Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacySAN…

RetinalGeniX Technologies, Inc. Acquires DNA/GPS Inc.

3 years ago

Acquisition of DNA-Based "GPS" Genetic Testing Combines with RTGN's High Resolution Retinal Imaging Technologies Seeks to Revolutionize Diagnosis of Systemic…